urosphere
News & events
UROsphere will present scientific results at the European Association for Urology Annual Meeting, Stockholm, Sweden from 11 to 15 April 2014.
Dr Julien Allard (E-phys) will present the Poster entitled "Dapoxetine inhibits erectile responses to stimulation of cavernous nerve in rats: a new hypothesis for its effects on ejaculation" (final abstract #497). The poster will be presented at Poster Session 40 (room T1) on Sunday, 13 April 2014 from 12:15 to 13:45.
Urosphere has developed new experimental models for Erectile Dysfunctions
UROsphere has recently established a scientific collaboration with Dr. Julien Allard, Founder and Chief Scientific Officer of E-Phys, an in vivo electrophysiological platform located in Clermont-Ferrand (France). Thanks to the scientific and technical expertise of Dr. Allard, an internationally reputed scientist specialized in the study of male and female sexual function, UROsphere can now offer experimental models for the assessment of drug treatment on erectile function in rats or mice: Drug...
UROsphere presents scientific results at the International Continence Society (ICS) annual meeting (Barcelona, Spain, 26 – 30 August 2013).
The following scientific results will be presented : DFL 14817, a new potent and selective TRPM8 antagonist for the treatment of urinary bladder disorders.Palea S1, Guilloteau V1, Brandolini L2, Guardia M1, Rollet K1, Guerard M1, Bianchini G2, Lluel P1, Aramini A2.1. UROsphere, 2. Dompé S.p.A.Podium Session 3 - Basic Science 1: InnovationsWednesday 28th August 2013 - 11:05-12:05. Modulation of PGE2-augmented micro-contractions by the non-selective ß-adrenoceptor agonist isoprenaline in...
UROsphere will present scientific results at the International Symposium on Prostate, Androgens and Men’s Sexual Health, which will take place in Berlin, Germany from 21 to 23 June 2013.
Dr Julien Allard will present the Unmoderated Poster entitled " Mice with null leptin receptor as a translational model of type II diabetes induced erectile dysfunction: in vivo assessment and effect of sildenafil " (final abstract #38). The poster exhibition will be located in meeting room "Postdam I and II" open to all delegates on: Friday 21 June 2013 11:00-19:30 hrs Saturday 22 June 2013 08:00-19:30 hrs UROsphere's Chief Scientific Officer, Stefano Palea,...
Urosphere takes parts in MAGenTA, a collaborative research project to develop innovative experimental models and clinical trials dedicated to urogenital diseases.
The MAGenTA project consists into a collaborative work between four SMEs and two academic institutions. The aim is to develop new and innovative predictive experimental models in order to provide pharmaceutical companies and academic research with better tools that should facilitate the validation of gene candidates and discovery of new molecules. MAGenTA also includes two clinical studies which will enable validation of the effectiveness of two therapeutic molecules for urogenital diseases....
UROsphere present scientific results at EAU 27th annual congress (Paris, France, 24-26 February 2012)
It is with pleasure that we will meet you at the booth 1N24, level 1, hall Passy. The following posters will be presented on Sunday, 26 February 2012 from 09h15 to 10h45. Effect of a selective β3-adrenergic agonist (CL-316, 243) on cystometric parameters in conscious spinal cord injured female rats. J.B. Beauval , V. Guilloteau , M. Capellini , A. Naudin , M. Guérard , P. Lluel , S. Palea , P. Rischmann , X. Gamé. Dose-dependent effect of a selective β3 adrenoreceptor agonist...
UROsphere presents scientific results at the 16th World Congress of Basic and Clinical Pharmacology (Copenhagen, Denmark, 17-23 July 2010)
The following posters will be presented: Comparison of the effects of AdTx1 and tamsulosin on the increase in intra-urethral and arterial pressures induced by phenylephrine in anesthetized male rats. Effects of duloxetine on bladder and external urethral sphincter in anesthetized female guinea-pigs with intravesical acetic acid. Stimulation of β3-adrenoceptors inhibits EFS-induced contractions of human isolated urinary bladder. Stimulation of both β2- and...
Urosphere unveils its new web site
UROsphere is pleased to present its new web site that has been redesigned to offer enhanced functionality to better fit with our clients’ needs: Quick access to our assays, models and expertise A restricted area dedicated to our clients Personalized filter by disease area listing pertinent publications Subscribe to our RSS feed to receive our news updates Feel free to contact us with any questions or comments, we will be happy to assist you.
Urosphere will attend ICS annual meeting and present several scientific communications. (Rotterdam, Netherlands, August 20-24, 2007)
View the posters presented. If you wish to meet UROsphere's senior managers during ICS meeting, please contact us.
UROsphere to present scientific results at ICS annual meeting (Egypt, 20-24 October 2008)
The following poster will be presented during the meeting: Palea S, Deba A, Lluel P. Activation of ß3-adrenoceptors inhibits neurogenic contraction in mouseisolated urinary bladder. UROsphere's top management will be present during the congress. If you wish to meet them, please contact us
UROsphere to present scientific results at EAU annual meeting (Stockholm, Sweden, 17-21 March , 2009)
UROsphere will take part in the European Association of Urology's Annual Meeting and present scientific results on BPH research: Gilles N, Lluel P, Rekik M, Guerard M, Palea S. AdTx1, a new peptidic α1-adrenoceptor antagonist with high affinity and selectivity for human α1A-adrenoceptor subtype: pharmacological characterization. The company's top managers will also present the company's expertise to members of the Medicon Valley biotech cluster (in Sweden and Denmark) in March 2009. To read...
UROsphere will be present at BIO EUROPE (Germany, 17-19th november 2008)
To meet UROsphere top management, please contact usFor more information on this event click here
UROsphere will be participating in Bio Japan 2008 (15-17 October 2008)
For more information on this event, click here .
UROsphere will be present at the CRO-Biotech BIOConnexion (Paris, 6th October 2008)
To meet us during this event, please contact usFor more information on this event organized by Info Veille Biotech, click here
SSR240600, a selective neurokinin NK1 receptor antagonist, reduces micturition frequency in anesthetized female guinea-pigs and may be useful as a treatment of human OAB.
Lluel P et al. Aspet-Ray Fuller Symposium, Lower Urinary Tract Disorders, July 6-7, 2002.